DSCAM-AS1: A Potential Drug Target and Biomarker (G100506492)

Target Name: DSCAM-AS1

NCBI ID: G100506492

DSCAM-AS1

Other Name(s): DSCAM antisense RNA 1, transcript variant 1 | M41 | DSCAM antisense RNA 1

DSCAM-AS1: A Potential Drug Target and Biomarker

DSCAM-AS1 (Dscam-As1) is a protein that is expressed in various tissues of the human body, including the brain, heart, and blood vessels. Its function is not well understood, but it is known to be involved in several cellular processes, including cell adhesion, migration, and survival. Based on these functions, DSCAM-AS1 has been identified as a potential drug target and biomarker.

DSCAM-AS1 Structure and Function

The structure of DSCAM-AS1 is unique, as it consists of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is responsible for domain-specific interactions with other proteins, while the C-terminal cytoplasmic domain is involved in the regulation of cellular processes.

One of the most interesting features of DSCAM-AS1 is its ability to interact with several different proteins, including the F-actinin protein. This interaction between DSCAM-AS1 and F-actinin suggests that DSCAM-AS1 may play a role in the regulation of actinin-mediated processes, such as cell migration and mechanical force generation.

DSCAM-AS1 has also been shown to interact with the protein known as p120GTP. This interaction suggests that DSCAM-AS1 may be involved in the regulation of p120GTP-mediated signaling pathways, which are involved in a wide range of cellular processes, including cell survival, angiogenesis, and inflammation.

DSCAM-AS1 has also been shown to interact with the protein known as CRL4-AS1. This interaction suggests that DSCAM-AS1 may be involved in the regulation of CRL4-AS1-mediated processes, which are involved in the regulation of gene expression and cellular processes that are critical for cell survival.

DSCAM-AS1 has been shown to play a role in the regulation of several cellular processes, including cell adhesion, migration, and survival. Based on these functions, DSCAM-AS1 has been identified as a potential drug target and biomarker.

DSCAM-AS1 as a Drug Target

The potential drug target for DSCAM-AS1 is based on its involvement in several cellular processes that are critical for cell survival and angiogenesis. DSCAM-AS1 has been shown to interact with several different proteins that are involved in the regulation of these processes, including actinin, p120GTP, and CRL4-AS1.

Actinin is a protein that is involved in the regulation of cell adhesion and migration. DSCAM-AS1 has been shown to interact with actinin, which suggests that DSCAM-AS1 may play a role in the regulation of actinin-mediated processes. This suggests that DSCAM-AS1 may be a useful target for drugs that are designed to modulateactinin-mediated processes.

PDGF-BB, which is a protein that is involved in the regulation of cell proliferation and survival, has also been shown to interact with DSCAM-AS1. This interaction suggests that DSCAM-AS1 may be involved in the regulation of PDGF-BB-mediated processes, which are important for cell survival and angiogenesis.

CLL-L, which is a protein that is involved in the regulation of cell lysosomal degradation, has also been shown to interact with DSCAM-AS1. This interaction suggests that DSCAM-AS1 may be involved in the regulation of CLL-L-mediated processes, which are important for the regulation of cell

Protein Name: DSCAM Antisense RNA 1

The "DSCAM-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DSCAM-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets